Maximo Agustin Schiavone: What Does ‘Risk-Factor-Free MI’ Really Mean in Practice?
Maximo Agustin Schiavone, Head of Clinical Research – Bariatric and Metabolic Surgery Department at Hospital Universitario Austral, shared a post on LinkedIn about a recent article by Daniel G. Brieger et al, published in Atherosclerosis:
“A ‘risk-factor-free’ heart attack is one of the most uncomfortable truths in preventive cardiology.
Because it exposes a category error we keep making: we treat risk factors as if they were the disease. But the disease is coronary atherosclerosis—and it can be present, active, and dangerous even when the usual checklist looks ‘clean.’
This review puts numbers on it: 14–25% of MI patients present without standard modifiable risk factors (SMuRFs), and SMuRFs explain only ~53–56% of incident CVD events globally. And the inequity signal is loud: SMuRF-less women with MI have nearly a threefold higher early mortality risk compared with men who have at least one risk factor.
So what does ‘risk-factor-free MI’ really mean in practice?
It often means ‘we missed the atherosclerosis’—because our prevention model is built to estimate risk, not to detect disease. The authors explicitly argue for moving beyond probability scores to directly detect the causal disease (atherosclerosis) before symptoms arise.
That framing matters: if you’re ‘SMuRF-less’ the correct clinical reflex shouldn’t be reassurance. It should be better phenotyping and a pathway that stops confusing ‘absence of classic risk factors’ with ‘absence of coronary disease.’
And yes, sex needs to be treated as a biological variable in the whole pipeline, because the performance gaps are most evident in women.”
Title: Coronary artery disease in the absence of standard modifiable risk factors (SMuRFs): The impact of sex
Authors: James Amamoo, Lin Xie, Andrea Steffens, Erin Buysman, Caroline Swift, Sherif Mehanna, Noelle N. Gronroos, Marc P. Bonaca
Read the Full Article on Atherosclerosis

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation